The brain is the most lipid-rich organ in the body, with lipids constituting ~50% of its dry weight. Brain lipids serve as structural components of membranes, signaling molecules, energy substrates, and regulators of protein function. Perturbations in lipid homeostasis — including altered cholesterol trafficking, sphingolipid imbalance, phospholipid remodeling, and fatty acid oxidation defects — are now recognized as convergent pathological features across Alzheimer's disease, Parkinson's disease, and multiple other neurodegenerative disorders[1]. The discovery that APOE, the strongest genetic risk factor for late-onset AD, encodes a lipid transport protein underscores the centrality of lipid metabolism in neurodegeneration[2].
The brain contains ~25% of total body cholesterol despite comprising only ~2% of body mass. Brain cholesterol is synthesized entirely de novo by astrocytes and oligodendrocytes because plasma cholesterol cannot cross the blood-brain barrier (BBB). Cholesterol is essential for:
Brain cholesterol is eliminated primarily via conversion to 24(S)-hydroxycholesterol (24-OHC) by CYP46A1, a neuron-specific enzyme. 24-OHC freely crosses the BBB and serves as a peripheral biomarker of brain cholesterol turnover[4].
Phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylserine (PS), and phosphatidylinositol (PI) form the structural basis of neuronal membranes. Key roles include:
Sphingolipids — ceramide, sphingomyelin, sphingosine-1-phosphate (S1P), glucosylceramide, and gangliosides — play regulatory roles in neurodegeneration:
APOE is the primary cholesterol transporter in the CNS, secreted by astrocytes as lipidated HDL-like particles. The three common isoforms (E2, E3, E4) differ in their lipid binding capacity:
Cholesterol- and sphingolipid-enriched membrane microdomains (lipid rafts) concentrate the amyloidogenic processing machinery. BACE1 and gamma-secretase (presenilin complex) are enriched in raft fractions, while non-amyloidogenic α-secretase (ADAM10) resides in non-raft regions. Membrane cholesterol levels directly modulate the balance between amyloidogenic and non-amyloidogenic APP processing[3:1].
The ceramide/S1P ratio acts as a molecular switch:
GBA1 mutations (heterozygous) are the most common genetic risk factor for PD (OR ~5–7). Reduced glucocerebrosidase (GCase) activity leads to glucosylceramide accumulation, which directly promotes alpha-synuclein aggregation. Conversely, alpha-synuclein aggregates inhibit GCase trafficking to lysosomes, creating a self-amplifying pathological cycle[8:1][11].
Lipid droplet (LD) accumulation in astrocytes and microglia is an emerging hallmark of neurodegeneration. Single-cell transcriptomics reveals lipid-droplet-associated microglia (LDAM) in aging and AD brain, characterized by upregulated lipid synthesis genes, impaired phagocytosis, and increased pro-inflammatory cytokine secretion[10:1]. In neurons, LD accumulation triggers ER stress and ferroptosis.
| Lipid Change | Direction | Consequence |
|---|---|---|
| Cholesterol in lipid rafts | ↑ | Enhanced Aβ production |
| Plasmalogens | ↓ 40–60% | Reduced antioxidant defense |
| Ceramide | ↑ 2–3x | BACE1 stabilization, apoptosis |
| Sulfatides | ↓ 90% in early AD | Myelin breakdown |
| 24-OHC (plasma) | ↑ early, ↓ late | Reflects neuronal cholesterol turnover |
| DHA (cortical) | ↓ | Impaired synaptic function, increased inflammation |
Over 50 lysosomal storage disorders demonstrate that primary lipid storage defects cause neurodegeneration:
Liver X receptor (LXR) activation promotes cholesterol efflux via ABCA1/ABCG1 transporters and increases APOE lipidation:
Di Paolo G, Kim TW. 'Linking lipids to Alzheimer''s disease: cholesterol and beyond'. Nature Reviews Neuroscience. 2011. ↩︎
Liu CC, Kanekiyo T, Xu H, Bu G. 'Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy'. Nature Reviews Neurology. 2013. ↩︎ ↩︎
Simons M, Keller P, De Strooper B, et al. Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proceedings of the National Academy of Sciences. 1998. ↩︎ ↩︎
Mast N, Saadane A, Valencia-Olvera A, et al. Cholesterol-metabolizing enzyme cytochrome P450 46A1 as a pharmacologic target for Alzheimer's disease. Neuroscience. 2017. ↩︎ ↩︎
Han X, Holtzman DM, McKeel DW Jr. 'Plasmalogen deficiency in early Alzheimer''s disease subjects and in animal models: molecular characterization using electrospray ionization mass spectrometry'. Journal of Neurochemistry. 2001. ↩︎
Puglielli L, Ellis BC, Saunders AJ, Bhatt DL. Ceramide stabilizes beta-site amyloid precursor protein-cleaving enzyme 1 and promotes amyloid beta-peptide biogenesis. Journal of Biological Chemistry. 2003. ↩︎ ↩︎
Yanagisawa K, Odaka A, Suzuki N, Ihara Y. 'GM1 ganglioside-bound amyloid beta-protein (A beta): a possible form of preamyloid in Alzheimer''s disease'. Nature Medicine. 1995. ↩︎
Mazzulli JR, Xu YH, Sun Y, et al. Gaucher disease glucocerebrosidase and alpha-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell. 2011. ↩︎ ↩︎ ↩︎
Cunnane SC, Plourde M, Pifferi F, et al. Fish, docosahexaenoic acid and Alzheimer's disease. Progress in Lipid Research. 2009. ↩︎
Marschallinger J, Iram T, Zardeneta M, et al. Lipid-droplet-accumulating microglia represent a dysfunctional and proinflammatory state in the aging brain. Nature Neuroscience. 2020. ↩︎ ↩︎
Sidransky E, Nalls MA, Aasly JO, et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. New England Journal of Medicine. 2009. ↩︎
Fusco G, De Simone A, Gopinath T, et al. Direct observation of the three regions in alpha-synuclein that determine its membrane-bound behaviour. Nature Communications. 2014. ↩︎
Shepardson NE, Bhatt DL, Bhatt A. 'Cholesterol level and statin use in Alzheimer disease: I. Review of epidemiological and preclinical studies'. Archives of Neurology. 2011. ↩︎
Mullin S, Smith L, Lee K, et al. 'Ambroxol for the treatment of patients with Parkinson disease with and without glucocerebrosidase gene mutations: a nonrandomized, noncontrolled trial'. JAMA Neurology. 2020. ↩︎
Zelcer N, Khanlou N, Clare R, et al. Attenuation of neuroinflammation and Alzheimer's disease pathology by liver x receptors. Proceedings of the National Academy of Sciences. 2007. ↩︎